CO6260104A2 - Anticuerpos contra la il-25 - Google Patents
Anticuerpos contra la il-25Info
- Publication number
- CO6260104A2 CO6260104A2 CO09123670A CO09123670A CO6260104A2 CO 6260104 A2 CO6260104 A2 CO 6260104A2 CO 09123670 A CO09123670 A CO 09123670A CO 09123670 A CO09123670 A CO 09123670A CO 6260104 A2 CO6260104 A2 CO 6260104A2
- Authority
- CO
- Colombia
- Prior art keywords
- binding member
- target binding
- seq
- domain
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1.- Un miembro de unión a diana que se une a IL-25 y que comprende un dominio VH de anticuerpo que comprende una CDR3 de VH que tiene una secuencia de aminoácidos sustancialmente como la indicada en la SEC ID N°: 7.2.- El miembro de unión a diana de la reivindicación 1, donde el dominio VH comprende además una CDR1 que tiene una secuencia de aminoácidos sustancialmente como la indicada en la SEC ID N°: 5 y una CDR2 que tiene una secuencia de aminoácidos sustancialmente como la indicada en la SEC ID N°: 6.3.- El miembro de unión a diana de la reivindicación 1, donde el dominio VH comprende una región flanqueante humana.4.- El miembro de unión a diana de la reivindicación 1, donde el dominio VH comprende la SEC ID N°: 2.5.- El miembro de unión a diana de la reivindicación 1, que comprende además un dominio VL con una CDR1 que tiene una secuencia de aminoácidos sustancialmente como la indicada en la SEC ID N°: 8, una CDR2 que tiene una secuencia de aminoácidos sustancialmente como la indicada en la SEC ID N°: 9 y una CDR3 que tiene una secuencia de aminoácidos sustancialmente como la indicada en la SEC ID N°: 10.6.- El miembro de unión a diana de la reivindicación 5, donde el dominio VL comprende una región flanqueante humana.7.- El miembro de unión a diana de la reivindicación 5, donde el dominio VL comprende la SEC ID N°: 4.8.- El miembro de unión a diana de la reivindicación 1, que es un fragmento de anticuerpo Fab, F(ab')2 o scFV.9.- El miembro de unión a diana de la reivindicación 1, que comprende una región constante de anticuerpo.10.- El miembro de unión a diana de la reivindicación 9, donde la región constante es una región constante de IgG1 o IgG4.11.- El miembro de unión a diana de la reivindicación 9, que comprende un anticuerpo entero.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91247407P | 2007-04-18 | 2007-04-18 | |
| GBGB0707505.4A GB0707505D0 (en) | 2007-04-18 | 2007-04-18 | Antibodies against il-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6260104A2 true CO6260104A2 (es) | 2011-03-22 |
Family
ID=38135020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09123670A CO6260104A2 (es) | 2007-04-18 | 2009-11-03 | Anticuerpos contra la il-25 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US8206717B2 (es) |
| EP (1) | EP2144934B1 (es) |
| JP (1) | JP5366930B2 (es) |
| KR (1) | KR101605861B1 (es) |
| CN (1) | CN101711256B (es) |
| AU (1) | AU2008240436B2 (es) |
| BR (1) | BRPI0810418A8 (es) |
| CA (1) | CA2684492C (es) |
| CO (1) | CO6260104A2 (es) |
| CR (1) | CR11079A (es) |
| CY (1) | CY1118244T1 (es) |
| DK (1) | DK2144934T3 (es) |
| EA (1) | EA018073B1 (es) |
| EC (1) | ECSP099726A (es) |
| ES (1) | ES2604255T3 (es) |
| GB (1) | GB0707505D0 (es) |
| GT (1) | GT200900271A (es) |
| HN (1) | HN2009003038A (es) |
| HR (1) | HRP20161548T1 (es) |
| HU (1) | HUE030935T2 (es) |
| IL (1) | IL201552A (es) |
| LT (1) | LT2144934T (es) |
| MX (1) | MX2009011234A (es) |
| MY (1) | MY148451A (es) |
| NI (1) | NI200900189A (es) |
| NZ (1) | NZ581178A (es) |
| PL (1) | PL2144934T3 (es) |
| PT (1) | PT2144934T (es) |
| RS (1) | RS55401B1 (es) |
| SI (1) | SI2144934T1 (es) |
| UA (1) | UA100377C2 (es) |
| WO (1) | WO2008129263A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0817891D0 (en) * | 2008-09-30 | 2008-11-05 | Medical Res Council | Antibodies against il-25 |
| US8574582B2 (en) * | 2008-10-31 | 2013-11-05 | Janssen Biotech, Inc. | Methods for mediating fibrotic response |
| GB0905972D0 (en) | 2009-04-06 | 2009-05-20 | Medical Res Council | Antibodies against IL-17BR |
| EP2477647B1 (en) | 2009-09-14 | 2016-01-13 | The Regents of the University of Colorado | Modulation of yeast-based immunotherapy products and responses |
| WO2011123507A1 (en) * | 2010-03-30 | 2011-10-06 | Centocor Ortho Biotech Inc. | Humanized il-25 antibodies |
| US9546219B2 (en) | 2012-02-08 | 2017-01-17 | North Carolina State University | Treatment of allergic diseases with recombinant antibodies |
| JP6250351B2 (ja) * | 2013-09-30 | 2017-12-20 | シスメックス株式会社 | 好酸球性気道炎症に関する情報の取得方法およびそのような情報を取得するためのマーカー |
| CN103792375B (zh) * | 2014-01-29 | 2017-07-07 | 华中科技大学同济医学院附属同济医院 | 外周血白细胞介素25水平在哮喘分型中的应用及分型方法 |
| CA2961517C (en) * | 2014-09-23 | 2023-05-02 | Regeneron Pharmaceuticals, Inc. | Anti-il-25 antibodies and uses thereof |
| KR102477922B1 (ko) * | 2016-03-16 | 2022-12-14 | 아베오미 코포레이션 | Il-25에 대한 중화 모노클로날 항체 및 그의 용도 |
| WO2018017864A2 (en) * | 2016-07-20 | 2018-01-25 | Oncomed Pharmaceuticals, Inc. | Pvrig-binding agents and uses thereof |
| US11285191B2 (en) | 2016-07-26 | 2022-03-29 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Immunostimulatory compositions and uses therefor |
| WO2018089335A1 (en) | 2016-11-09 | 2018-05-17 | North Carolina State University | Treatment of allergic diseases with chimeric protein |
| US20210332123A1 (en) * | 2018-11-19 | 2021-10-28 | Suzhou Kanova Biopharmaceutical Co., Ltd. | Anti-il-25 antibodies and use thereof |
| GB202018015D0 (en) | 2020-11-16 | 2020-12-30 | Res & Innovation Uk | Composition and methods for the treatment of intestinal cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6569645B2 (en) | 1999-05-14 | 2003-05-27 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| CN1289668C (zh) * | 2003-06-12 | 2006-12-13 | 北京安波特基因工程技术有限公司 | 一种用于抗体改形的体外分子定向进化方法 |
| WO2006094384A1 (en) | 2005-03-08 | 2006-09-14 | Genesense Technologies Inc. | Use of interleukin 17e for the treatment of cancer |
| US20070237763A1 (en) | 2005-10-06 | 2007-10-11 | Baylor Research Institute | Compositions and methods for the treatment of cancer |
| GB0817891D0 (en) | 2008-09-30 | 2008-11-05 | Medical Res Council | Antibodies against il-25 |
-
2007
- 2007-04-18 GB GBGB0707505.4A patent/GB0707505D0/en not_active Ceased
-
2008
- 2008-04-17 BR BRPI0810418A patent/BRPI0810418A8/pt not_active Application Discontinuation
- 2008-04-17 LT LTEP08737025.0T patent/LT2144934T/lt unknown
- 2008-04-17 CA CA2684492A patent/CA2684492C/en not_active Expired - Fee Related
- 2008-04-17 DK DK08737025.0T patent/DK2144934T3/en active
- 2008-04-17 HU HUE08737025A patent/HUE030935T2/en unknown
- 2008-04-17 WO PCT/GB2008/001365 patent/WO2008129263A1/en active Application Filing
- 2008-04-17 ES ES08737025.0T patent/ES2604255T3/es active Active
- 2008-04-17 EA EA200901421A patent/EA018073B1/ru not_active IP Right Cessation
- 2008-04-17 MY MYPI20094358A patent/MY148451A/en unknown
- 2008-04-17 KR KR1020097023939A patent/KR101605861B1/ko active IP Right Grant
- 2008-04-17 RS RS20161009A patent/RS55401B1/sr unknown
- 2008-04-17 JP JP2010503589A patent/JP5366930B2/ja not_active Expired - Fee Related
- 2008-04-17 CN CN2008800206204A patent/CN101711256B/zh not_active Expired - Fee Related
- 2008-04-17 US US12/596,053 patent/US8206717B2/en active Active
- 2008-04-17 SI SI200831698A patent/SI2144934T1/sl unknown
- 2008-04-17 PT PT87370250T patent/PT2144934T/pt unknown
- 2008-04-17 EP EP08737025.0A patent/EP2144934B1/en active Active
- 2008-04-17 MX MX2009011234A patent/MX2009011234A/es active IP Right Grant
- 2008-04-17 NZ NZ581178A patent/NZ581178A/en not_active IP Right Cessation
- 2008-04-17 PL PL08737025T patent/PL2144934T3/pl unknown
- 2008-04-17 AU AU2008240436A patent/AU2008240436B2/en not_active Ceased
- 2008-04-17 UA UAA200911796A patent/UA100377C2/ru unknown
-
2009
- 2009-10-15 IL IL201552A patent/IL201552A/en active IP Right Grant
- 2009-10-16 HN HN2009003038A patent/HN2009003038A/es unknown
- 2009-10-16 GT GT200900271A patent/GT200900271A/es unknown
- 2009-10-16 NI NI200900189A patent/NI200900189A/es unknown
- 2009-10-28 CR CR11079A patent/CR11079A/es unknown
- 2009-11-03 CO CO09123670A patent/CO6260104A2/es active IP Right Grant
- 2009-11-10 EC EC2009009726A patent/ECSP099726A/es unknown
-
2016
- 2016-11-17 CY CY20161101187T patent/CY1118244T1/el unknown
- 2016-11-22 HR HRP20161548TT patent/HRP20161548T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6260104A2 (es) | Anticuerpos contra la il-25 | |
| HRP20191462T1 (hr) | Antitijela usmjerena protiv her-3 i njihove uporabe | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| PE20091342A1 (es) | Inmunoglobulinas | |
| TR201901929T4 (tr) | TGFBeta'ya antikorlar. | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| HRP20211444T1 (hr) | Anti-dll3 antitijelo | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| RS53760B1 (en) | HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| HRP20150439T1 (hr) | Protutijela za humani angiopoietin 2 | |
| RS53819B1 (en) | ANTI-ACTIVIN ANTIBODIES AND THEIR APPLICATIONS | |
| NZ602780A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| RS52860B (en) | ANTI-ILT7 ANTITELO | |
| NZ628923A (en) | Targeted binding agents against b7-h1 | |
| NZ603581A (en) | Anti-gd2 antibodies | |
| RS54259B1 (en) | HAVE AUTOANTITELA ACHIEVEMENTS | |
| RS54424B1 (en) | HUMAN ANTIBODIES CONCERNING CXCR4 AND THEIR USES | |
| NZ595235A (en) | Compositions and methods for increasing muscle growth | |
| PE20081185A1 (es) | Anticuerpos que se unen a interleucina 13 (il-13) humana y composiciones farmaceuticas que lo comprenden | |
| AU2018272852A8 (en) | Antibodies comprising modified heavy constant regions | |
| RS53263B (en) | CD19 OPTIMIZED ANTIBODY | |
| PE20091269A1 (es) | Moleculas de union al receptor ox40 humano | |
| PE20141398A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| PE20090329A1 (es) | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |